Evidence map›Paper›PMID 29618560›Full record

Trial reportScience translational medicine2018

A bioengineered retinal pigment epithelial monolayer for advanced, dry age-related macular degeneration.

Amir H Kashani, Jane S Lebkowski, Firas M Rahhal, Robert L Avery, Hani Salehi-Had, Wei Dang, Chih-Min Lin, Debbie Mitra, Danhong Zhu, Biju B Thomas and 6 more

Abstract readClinical Trial, Phase IClinical Trial, Phase II
PubMed Publisher
In one paragraph

Trial report in Science translational medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 212 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
212citing papers in PubMed, 4 pooled it
16.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

212 citing papers in PubMed, 4 syntheses or guidelines pooled it, 379 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Review
  11. Article
  12. 3D epigenomic landscape of the human retinal pigment epithelium.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  13. Neural Vision Restoration in Ophthalmology.Annals of biomedical engineering · 2026
    Review
  14. Review
  15. Cell therapy for age-related macular degeneration.Mammalian genome : official journal of the International Mammalian Genome Society · 2026
    Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article

152 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 7 institutions in 2 countries.

Amir H KashaniUniversity of Southern California (USC) Roski Eye Institute, USC Institute for Biomedical Therapeutics, and Department of Ophthalmology, Keck School of Medicine, USC, 1450 San Pablo, Los Angeles, CA 90033, USA. humayun@usc.edu ahkashan@usc.edu.ORCID 0000-0001-9767-7920
Jane S LebkowskiRegenerative Patch Technologies, 150 Gabarda Way, Portola Valley, CA 94028-7445, USA.
Firas M RahhalRetina Vitreous Associates Medical Group, 9001 Wilshire Boulevard, Suite 301, Beverly Hills, CA 90211, USA.
Robert L AveryCalifornia Retina Consultants, 525 East Micheltorena Street, Santa Barbara, CA 93103, USA.
Hani Salehi-HadAtlantis Eyecare, 7777 Edinger Avenue, Suite 234, Huntington Beach, CA 92647, USA.ORCID 0000-0003-2631-7754
Wei DangCenter for Biomedicine and Genetics, Beckman Research Institute of City of Hope, 1500 East Duarte Road, Duarte, CA 91010, USA.
Chih-Min LinCenter for Biomedicine and Genetics, Beckman Research Institute of City of Hope, 1500 East Duarte Road, Duarte, CA 91010, USA.ORCID 0000-0003-2062-5131
Debbie MitraUniversity of Southern California (USC) Roski Eye Institute, USC Institute for Biomedical Therapeutics, and Department of Ophthalmology, Keck School of Medicine, USC, 1450 San Pablo, Los Angeles, CA 90033, USA.ORCID 0000-0002-4919-5991
Danhong ZhuDepartment of Pathology, Keck School of Medicine, USC, 1441 Eastlake Avenue, NRT 7503, Los Angeles, CA 90033, USA.
Biju B ThomasUniversity of Southern California (USC) Roski Eye Institute, USC Institute for Biomedical Therapeutics, and Department of Ophthalmology, Keck School of Medicine, USC, 1450 San Pablo, Los Angeles, CA 90033, USA.
Sherry T HikitaCenter for Stem Cell Biology and Engineering, Neuroscience Research Institute, Mail Code 5060, University of California, Santa Barbara, CA 93016, USA.
Britney O PenningtonCenter for Stem Cell Biology and Engineering, Neuroscience Research Institute, Mail Code 5060, University of California, Santa Barbara, CA 93016, USA.
Lincoln V JohnsonRegenerative Patch Technologies, 150 Gabarda Way, Portola Valley, CA 94028-7445, USA.
Dennis O CleggCenter for Stem Cell Biology and Engineering, Neuroscience Research Institute, Mail Code 5060, University of California, Santa Barbara, CA 93016, USA.ORCID 0000-0003-1231-590X
David R HintonUniversity of Southern California (USC) Roski Eye Institute, USC Institute for Biomedical Therapeutics, and Department of Ophthalmology, Keck School of Medicine, USC, 1450 San Pablo, Los Angeles, CA 90033, USA.
Mark S HumayunUniversity of Southern California (USC) Roski Eye Institute, USC Institute for Biomedical Therapeutics, and Department of Ophthalmology, Keck School of Medicine, USC, 1450 San Pablo, Los Angeles, CA 90033, USA. humayun@usc.edu ahkashan@usc.edu.ORCID 0000-0002-5830-5208
Keck Hospital of USC · USUniversity of California, Santa Barbara · USCity of Hope · USCalifornia Institute for Regenerative Medicine · USCalifornia Retina Consultants · USGolden West College · USRetina Vitreous Associates Medical Group · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Retinal pigment epithelium (RPE) dysfunction and loss are a hallmark of non-neovascular age-related macular degeneration (NNAMD). Without the RPE, a majority of overlying photoreceptors ultimately degenerate, leading to severe, progressive vision loss. Clinical and histological studies suggest that RPE replacement strategies may delay disease progression or restore vision. A prospective, interventional, U.S. Food and Drug Administration-cleared, phase 1/2a study is being conducted to assess the safety and efficacy of a composite subretinal implant in subjects with advanced NNAMD. The composite implant, termed the California Project to Cure Blindness-Retinal Pigment Epithelium 1 (CPCB-RPE1), consists of a polarized monolayer of human embryonic stem cell-derived RPE (hESC-RPE) on an ultrathin, synthetic parylene substrate designed to mimic Bruch's membrane. We report an interim analysis of the phase 1 cohort consisting of five subjects. Four of five subjects enrolled in the study successfully received the composite implant. In all implanted subjects, optical coherence tomography imaging showed changes consistent with hESC-RPE and host photoreceptor integration. None of the implanted eyes showed progression of vision loss, one eye improved by 17 letters and two eyes demonstrated improved fixation. The concurrent structural and functional findings suggest that CPCB-RPE1 may improve visual function, at least in the short term, in some patients with severe vision loss from advanced NNAMD.

Indexed as

Cells, CulturedFemaleGeographic AtrophyHuman Embryonic Stem CellsHumansMacular DegenerationMaleProspective StudiesRetinal Pigment EpitheliumStem Cell TransplantationTomography, Optical Coherence

Identifiers

PMID29618560
OpenAlexW2795836363

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.